Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Sector

Healthcare

Industry

Biotechnology

CEO

Kaupinen, Wesley

Employees

Website

palvellatx.com

IPO Date

2015-01-02

Headquarters

125 Strafford Avenue, Suite 360, Wayne, Pennsylvania, 19087, United States

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Palvella Therapeutics PVLA

Palvella Therapeutics Earnings Call Summary

Palvella Therapeutics Earnings

Transcripts

Events

About Palvella Therapeutics, Inc.

Palvella Therapeutics
PVLA